China Jo-Jo Drugstores Inc Stock Price, News & Analysis

China Jo-Jo Drugstores (Nasdaq: CJJD) announced the termination of a previously proposed registered direct offering of 2,258,888 ordinary shares and registered warrants for up to 4,517,776 shares to an institutional investor. This decision means no securities were sold under the Company's shelf registration statement on Form F-3 (No. 333-259692). The press release emphasizes the Company's role as a leading retailer and wholesale distributor of pharmaceutical products, along with healthcare services in China. Jo-Jo Drugstores operates both online and offline pharmacies, providing healthcare consultations. The Company also cautioned about various risks that may affect its future performance, such as competition and the ability to secure additional funding.

China Jo-Jo Drugstores, Inc. (Nasdaq: CJJD) announced a definitive agreement with an institutional investor for a registered direct offering of 2,258,888 ordinary shares at a price of $3.10 per share, yielding approximately $7 million in gross proceeds. The agreement also includes warrants for the purchase of up to 4,517,776 additional shares at the same exercise price, valid for five years. The offering is set to close around April 20, 2023, pending customary conditions. Proceeds will be utilized for general corporate purposes and working capital. Maxim Group LLC serves as the placement agent for this offering. This transaction is conducted under a shelf registration statement effective since December 19, 2022.

China Jo-Jo Drugstores, Inc. (Nasdaq: CJJD) announced a registered direct offering of 1.75 million ordinary shares at $1.50 each, generating gross proceeds of $2.625 million. Alongside this, the company will issue warrants for 5.25 million shares with an exercise price of $2.50, valid for three years. The closing of this offering is anticipated on January 24, 2023, pending standard conditions. The proceeds will be used for general corporate purposes and working capital. The offering is made under a shelf registration statement effective December 19, 2022.

China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) reported a robust fiscal year 2022 with total revenue rising 23.5% to $164.39 million and gross profit increasing 24.9% to $36.52 million. The net loss narrowed significantly by 61.8% to $3.20 million as operational losses improved. The growth stems from the retail drugstores, online pharmacy, and wholesale business segments. The Company aims to leverage its strategic initiatives, including digital services and enhanced management systems, to capture opportunities presented by the 'Healthy China 2030' initiative.

China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) announced on April 27, 2022 that it has regained compliance with Nasdaq's minimum bid price requirement. Following a 1-for-12 reverse stock split effective April 7, 2022, the company maintained a closing bid price above $1.00 for 11 consecutive business days up to April 22, 2022. This resolution closes the matter originally initiated on July 26, 2021, when the company was first notified of non-compliance.

China Jo-Jo Drugstores (CJJD) announced a 1-for-12 reverse stock split effective April 7, 2022. This means every 12 existing shares will convert to 1 share, affecting all shareholders uniformly. Fractional shares will round up to the nearest whole share. This decision was approved by the board and shareholders, aiming to enhance the stock's marketability and comply with listing requirements on the Nasdaq Capital Market. The new CUSIP number will be G2124G 112.